

3 April 2024

Privatisation by way of scheme of arrangement

Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

Party	Date	Description	Description	Nature of	Number of	Maturity	Reference	Total amount	Resultant
		of relevant	of products	dealings	reference	date /	price	paid / received	balance
		securities			securities	closing			(including
					to which	out date			those of any
					the				person with
					derivatives				whom there is
					relate				an agreement
									or
									understanding)
China	2 April 2024	Derivatives	Other types	Closing out of	300,000	2 April	\$17.8299	\$5,348,970.0000	0
International			of products	a derivative		2024			
Capital				contract					
Corporation									
Limited									



Derivatives	Other types	Closing out of	200,000	2 April	\$17.8299	\$3,565,980.0000	0
	of products	a derivative		2024			
		contract					
Derivatives	Other types	Closing out of	300,000	2 April	\$17.8299	\$5,348,970.0000	0
	of products	a derivative		2024			
		contract					
Derivatives	Other types	Closing out of	200,000	2 April	\$17.8299	\$3,565,980.0000	0
	of products	a derivative		2024			
		contract					

End

Note:

China International Capital Corporation Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

China International Capital Corporation Limited is ultimately owned by China International Capital Corporation Limited.